INVA
Innoviva, Inc.
Price Chart
Latest Quote
$23.34
-0.30 (-1.27%)
Current Price
| Previous Close | $23.64 |
| Open | $23.97 |
| Day High | $23.97 |
| Day Low | $23.26 |
| Volume | 216,222 |
Stock Information
| Shares Outstanding | 73.81M |
| Total Debt | $331.42M |
| Cash Equivalents | $611.93M |
| Revenue | $420.69M |
| Net Income | $504.34M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.72B |
| P/E Ratio | 3.73 |
| EPS (TTM) | $6.26 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.46B |
| Sales | $420.69M |
| Income | $504.34M |
| Book/sh | $18.18 |
| Cash/sh | $8.29 |
| Employees | 159 |
Financial Ratios
| Quick Ratio | 19.27 |
| Current Ratio | 21.13 |
| Debt/Eq | 24.70 |
Returns & Margins
| ROA | 6.72% |
| ROE | 50.72% |
| Gross Margin | 74.10% |
| Operating Margin | 40.11% |
| Profit Margin | 119.88% |
Ownership
| Insider Ownership | 0.99% |
| Institutional Ownership | 108.03% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 10.56 |
| PEG | 0.34 |
| P/S | 4.09 |
| P/B | 1.28 |
Analyst Data
| Recommendation | buy |
| Target Price | $35.50 |
Technical Indicators
| SMA20 | $22.45 |
| SMA50 | $22.75 |
| SMA200 | $21.11 |
| RSI | 63.98 |
| ATR | 0.6521 |
| Shares Float | 69.19M |
| Short Float | 10.70% |
| Short Ratio | 7.49 |
| Volatility | 0.35 |
| Rel Volume | 0.25 |
Performance History
| Week | +3.09% |
| Month | +2.91% |
| Quarter | +3.32% |
| 6 Months | +16.76% |
| YTD | +17.46% |
| Year | +12.86% |
| 3 Years | +82.06% |
| 5 Years | +80.09% |
| 10 Years | +135.52% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-25 | $23.34 | 216,222 |
| 2026-06-24 | $23.64 | 841,200 |
| 2026-06-23 | $23.55 | 635,300 |
| 2026-06-22 | $22.67 | 911,200 |
| 2026-06-18 | $22.49 | 1,403,800 |
| 2026-06-17 | $22.64 | 588,400 |
| 2026-06-16 | $22.61 | 564,700 |
| 2026-06-15 | $22.42 | 709,800 |
| 2026-06-12 | $22.74 | 557,700 |
| 2026-06-11 | $22.44 | 762,800 |
| 2026-06-10 | $23.00 | 727,500 |
| 2026-06-09 | $22.54 | 738,500 |
| 2026-06-08 | $22.33 | 913,500 |
| 2026-06-05 | $22.52 | 845,400 |
| 2026-06-04 | $22.16 | 720,200 |
| 2026-06-03 | $21.70 | 909,800 |
| 2026-06-02 | $21.35 | 1,047,100 |
| 2026-06-01 | $21.51 | 1,860,200 |
| 2026-05-29 | $21.42 | 1,164,200 |
| 2026-05-28 | $21.89 | 1,276,300 |
| 2026-05-27 | $22.13 | 597,500 |
| 2026-05-26 | $22.68 | 901,400 |
About Innoviva, Inc.
Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
đ° Latest News
Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform
Insider Monkey âĸ 2026-06-25T12:42:51Z
Innoviva Specialty Therapeutics (INVA) Partners With Dr. Reddyâs to Expand XACDURO Access Internationally
Insider Monkey âĸ 2026-06-23T17:54:46Z
Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More
Motley Fool âĸ 2026-05-29T22:55:31Z
Is Innoviva (INVA) Pricing Look Compelling After Recent Share Price Softness?
Simply Wall St. âĸ 2026-05-11T10:08:09Z
Innoviva, Inc. (INVA) Draws Bullish View from Cantor on Recurring Royalty Strength
Insider Monkey âĸ 2026-05-08T21:01:44Z
Innoviva (INVA) Tops Q1 Earnings Estimates
Zacks âĸ 2026-05-07T01:45:06Z
3 Bargain-Cheap Small Caps Worth a Second Look
MarketBeat âĸ 2026-04-09T12:24:00Z
Analysts See This Pharma Stock Surging 60%; Eyes Fresh Entry
Investor's Business Daily âĸ 2026-04-02T18:03:29Z
Is It Time To Revisit Innoviva (INVA) After Strong Multi Year Share Price Gains
Simply Wall St. âĸ 2026-03-24T08:06:30Z
Mutiny At Aurinia Pharmaceuticals? Biotech Rallies On C-Suite Shake-Up
Investor's Business Daily âĸ 2026-03-23T20:05:24Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $77,384,000 | $36,598,000 | $42,640,000 | $13,793,000 |
| Cost Of Revenue | $77,384,000 | $36,598,000 | $42,640,000 | $13,793,000 |
| Total Revenue | $411,328,000 | $358,711,000 | $310,463,000 | $331,339,000 |
| Operating Revenue | $411,328,000 | $358,711,000 | $310,463,000 | $331,339,000 |
| Expenses | ||||
| Interest Expense | $16,698,000 | $22,209,000 | $19,157,000 | $15,789,000 |
| Total Expenses | $247,583,000 | $191,844,000 | $196,578,000 | $124,344,000 |
| Other Income Expense | $158,729,000 | $-126,411,000 | $83,552,000 | $89,374,000 |
| Other Non Operating Income Expenses | $-2,864,000 | $-2,997,000 | $-4,969,000 | $-3,373,000 |
| Net Non Operating Interest Income Expense | $4,388,000 | $-3,068,000 | $-3,339,000 | $-9,420,000 |
| Interest Expense Non Operating | $16,698,000 | $22,209,000 | $19,157,000 | $15,789,000 |
| Operating Expense | $170,199,000 | $155,246,000 | $153,938,000 | $110,551,000 |
| General And Administrative Expense | - | - | - | $63,538,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $271,165,000 | $23,392,000 | $179,722,000 | $213,921,000 |
| Net Interest Income | $4,388,000 | $-3,068,000 | $-3,339,000 | $-9,420,000 |
| Interest Income | $21,086,000 | $19,141,000 | $15,818,000 | $6,369,000 |
| Normalized Income | $254,432,200 | $60,367,625 | $169,417,277 | $18,569,917 |
| Net Income From Continuing And Discontinued Operation | $271,165,000 | $23,392,000 | $179,722,000 | $213,921,000 |
| Total Operating Income As Reported | $163,745,000 | $166,867,000 | $113,885,000 | $-36,946,000 |
| Average Dilution Earnings | $8,658,000 | $3,468,000 | $11,582,000 | $11,648,000 |
| Net Income Common Stockholders | $271,165,000 | $23,392,000 | $179,722,000 | $213,921,000 |
| Net Income | $271,165,000 | $23,392,000 | $179,722,000 | $213,921,000 |
| Net Income Including Noncontrolling Interests | $271,165,000 | $23,392,000 | $179,722,000 | $220,262,000 |
| Net Income Continuous Operations | $271,165,000 | $23,392,000 | $179,722,000 | $220,262,000 |
| Pretax Income | $326,862,000 | $37,388,000 | $194,098,000 | $286,949,000 |
| Earnings From Equity Interest | $141,433,000 | $-64,253,000 | $77,392,000 | $-161,749,000 |
| Interest Income Non Operating | $21,086,000 | $19,141,000 | $15,818,000 | $6,369,000 |
| Operating Income | $163,745,000 | $166,867,000 | $113,885,000 | $206,995,000 |
| Depreciation Amortization Depletion Income Statement | $26,277,000 | $25,902,000 | $21,784,000 | $5,581,000 |
| Depreciation And Amortization In Income Statement | $26,277,000 | $25,902,000 | $21,784,000 | $5,581,000 |
| Amortization Of Intangibles Income Statement | $26,277,000 | $25,902,000 | $21,784,000 | $5,581,000 |
| Gross Profit | $333,944,000 | $322,113,000 | $267,823,000 | $317,546,000 |
| Special Income Charges | - | $0 | $0 | $246,034,000 |
| Per Share | ||||
| Diluted EPS | $3.30 | $0.36 | $2.20 | $2.37 |
| Basic EPS | $4.02 | $0.37 | $2.75 | $3.07 |
| Other | ||||
| Tax Effect Of Unusual Items | $3,427,200 | $-22,185,375 | $824,277 | $59,144,917 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $349,677,000 | $144,660,000 | $223,910,000 | $53,823,000 |
| Total Unusual Items | $20,160,000 | $-59,161,000 | $11,129,000 | $254,496,000 |
| Total Unusual Items Excluding Goodwill | $20,160,000 | $-59,161,000 | $11,129,000 | $254,496,000 |
| Reconciled Depreciation | $26,277,000 | $25,902,000 | $21,784,000 | $5,581,000 |
| EBITDA (Bullshit earnings) | $369,837,000 | $85,499,000 | $235,039,000 | $308,319,000 |
| EBIT | $343,560,000 | $59,597,000 | $213,255,000 | $302,738,000 |
| Diluted Average Shares | $84,760,000 | $74,187,000 | $86,876,000 | $95,249,000 |
| Basic Average Shares | $67,395,000 | $62,726,000 | $65,435,000 | $69,644,000 |
| Diluted NI Availto Com Stockholders | $279,823,000 | $26,860,000 | $191,304,000 | $225,569,000 |
| Tax Provision | $55,697,000 | $13,996,000 | $14,376,000 | $66,687,000 |
| Gain On Sale Of Security | $20,160,000 | $-59,161,000 | $11,129,000 | $8,462,000 |
| Amortization | $26,277,000 | $25,902,000 | $21,784,000 | $5,581,000 |
| Research And Development | $30,604,000 | $13,654,000 | $33,922,000 | $41,432,000 |
| Selling General And Administration | $113,318,000 | $115,690,000 | $98,232,000 | $63,538,000 |
| Minority Interests | - | $0 | $0 | $-6,341,000 |
| Gain On Sale Of Business | - | $0 | $0 | $266,696,000 |
| Other Special Charges | - | - | - | $20,662,000 |
| Other Gand A | - | - | - | $63,538,000 |
Fetched: 2026-06-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $972,780,000 | $464,821,000 | $426,715,000 | $286,156,000 |
| Total Assets | $1,635,165,000 | $1,301,060,000 | $1,243,507,000 | $1,231,497,000 |
| Total Non Current Assets | $907,650,000 | $746,754,000 | $899,288,000 | $787,986,000 |
| Other Non Current Assets | $40,744,000 | $41,477,000 | $3,267,000 | $4,299,000 |
| Non Current Deferred Assets | $0 | $12,054,000 | $0 | $0 |
| Non Current Deferred Taxes Assets | $0 | $12,054,000 | $0 | $0 |
| Non Current Accounts Receivable | $56,138,000 | $69,961,000 | $83,784,000 | $97,607,000 |
| Goodwill And Other Intangible Assets | $200,061,000 | $226,338,000 | $248,240,000 | $279,632,000 |
| Other Intangible Assets | $182,156,000 | $208,433,000 | $230,335,000 | $252,919,000 |
| Current Assets | $727,515,000 | $554,306,000 | $344,219,000 | $443,511,000 |
| Other Current Assets | $1,637,000 | $656,000 | $4,264,000 | $2,933,000 |
| Prepaid Assets | $26,721,000 | $21,063,000 | $21,630,000 | $29,559,000 |
| Inventory | $39,172,000 | $33,725,000 | $40,737,000 | $55,897,000 |
| Receivables | $93,317,000 | $86,366,000 | $84,075,000 | $64,073,000 |
| Other Receivables | $58,351,000 | $65,974,000 | $69,621,000 | $54,672,000 |
| Accounts Receivable | $34,966,000 | $20,392,000 | $14,454,000 | $9,401,000 |
| Cash Cash Equivalents And Short Term Investments | $566,668,000 | $412,496,000 | $193,513,000 | $291,049,000 |
| Cash And Cash Equivalents | $550,941,000 | $304,964,000 | $193,513,000 | $291,049,000 |
| Investmentin Financial Assets | - | - | - | $403,013,000 |
| Debt | ||||
| Total Debt | $269,017,000 | $451,095,000 | $449,076,000 | $544,065,000 |
| Long Term Debt And Capital Lease Obligation | $268,599,000 | $257,495,000 | $447,869,000 | $446,556,000 |
| Long Term Debt | $257,731,000 | $256,316,000 | $446,234,000 | $444,180,000 |
| Current Debt And Capital Lease Obligation | $418,000 | $193,600,000 | $1,207,000 | $97,509,000 |
| Net Debt | - | $143,380,000 | $252,721,000 | $249,324,000 |
| Current Debt | - | $192,028,000 | - | $96,193,000 |
| Other Current Borrowings | - | $192,028,000 | - | $96,193,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $462,324,000 | $609,901,000 | $568,552,000 | $665,709,000 |
| Total Non Current Liabilities Net Minority Interest | $412,628,000 | $373,818,000 | $530,418,000 | $530,741,000 |
| Other Non Current Liabilities | $1,119,000 | - | $359,000 | $595,000 |
| Tradeand Other Payables Non Current | $57,013,000 | $53,227,000 | $11,751,000 | $9,872,000 |
| Non Current Deferred Liabilities | $85,897,000 | $63,096,000 | $70,439,000 | $73,718,000 |
| Non Current Deferred Taxes Liabilities | $31,793,000 | $0 | $563,000 | $5,771,000 |
| Current Liabilities | $49,696,000 | $236,083,000 | $38,134,000 | $134,968,000 |
| Other Current Liabilities | $-4,270,000 | $-1,126,000 | - | $2,639,000 |
| Current Deferred Liabilities | $12,394,000 | $7,564,000 | $1,277,000 | $4,733,000 |
| Payables And Accrued Expenses | $36,884,000 | $34,919,000 | $35,650,000 | $32,726,000 |
| Interest Payable | $1,618,000 | $3,422,000 | $3,422,000 | $4,359,000 |
| Payables | $8,930,000 | $5,083,000 | $8,645,000 | $3,093,000 |
| Other Payable | $3,690,000 | $2,951,000 | $1,928,000 | - |
| Total Tax Payable | $274,000 | $0 | $0 | $154,000 |
| Income Tax Payable | $274,000 | $0 | $0 | $154,000 |
| Accounts Payable | $4,966,000 | $2,132,000 | $6,717,000 | $2,939,000 |
| Equity | ||||
| Common Stock Equity | $1,172,841,000 | $691,159,000 | $674,955,000 | $565,788,000 |
| Total Equity Gross Minority Interest | $1,172,841,000 | $691,159,000 | $674,955,000 | $565,788,000 |
| Stockholders Equity | $1,172,841,000 | $691,159,000 | $674,955,000 | $565,788,000 |
| Retained Earnings | $269,368,000 | $-1,797,000 | $-25,189,000 | $-204,911,000 |
| Long Term Equity Investment | $598,223,000 | $393,957,000 | $560,978,000 | $403,013,000 |
| Other | ||||
| Ordinary Shares Number | $74,636,000 | $62,665,000 | $63,307,000 | $69,188,000 |
| Share Issued | $74,636,000 | $62,665,000 | $95,312,000 | $101,193,000 |
| Tangible Book Value | $972,780,000 | $464,821,000 | $426,715,000 | $286,156,000 |
| Invested Capital | $1,430,572,000 | $1,139,503,000 | $1,121,189,000 | $1,106,161,000 |
| Working Capital | $677,819,000 | $318,223,000 | $306,085,000 | $308,543,000 |
| Capital Lease Obligations | $11,286,000 | $2,751,000 | $2,842,000 | $3,692,000 |
| Total Capitalization | $1,430,572,000 | $947,475,000 | $1,121,189,000 | $1,009,968,000 |
| Additional Paid In Capital | $902,726,000 | $692,329,000 | $1,093,340,000 | $1,163,836,000 |
| Capital Stock | $747,000 | $627,000 | $633,000 | $692,000 |
| Common Stock | $747,000 | $627,000 | $633,000 | $692,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $10,868,000 | $1,179,000 | $1,635,000 | $2,376,000 |
| Current Deferred Revenue | $4,270,000 | $1,126,000 | $1,277,000 | $2,094,000 |
| Current Capital Lease Obligation | $418,000 | $1,572,000 | $1,207,000 | $1,316,000 |
| Current Accrued Expenses | $27,954,000 | $29,836,000 | $27,005,000 | $29,633,000 |
| Duefrom Related Parties Non Current | $56,138,000 | $69,961,000 | $83,784,000 | $97,607,000 |
| Investments And Advances | $598,223,000 | $393,957,000 | $560,978,000 | $403,013,000 |
| Goodwill | $17,905,000 | $17,905,000 | $17,905,000 | $26,713,000 |
| Net PPE | $12,484,000 | $2,967,000 | $3,019,000 | $3,435,000 |
| Gross PPE | $12,484,000 | $2,967,000 | $3,019,000 | $3,435,000 |
| Other Properties | $12,484,000 | $2,967,000 | $3,019,000 | $3,435,000 |
| Finished Goods | $4,971,000 | $2,083,000 | $13,810,000 | $25,088,000 |
| Work In Process | $17,871,000 | $20,529,000 | $15,670,000 | $25,052,000 |
| Raw Materials | $16,330,000 | $11,113,000 | $11,257,000 | $5,757,000 |
| Other Short Term Investments | $15,727,000 | $107,532,000 | $0 | - |
| Minority Interest | - | $0 | $0 | $0 |
| Treasury Stock | - | $0 | $393,829,000 | $393,829,000 |
| Treasury Shares Number | - | - | $32,005,000 | $32,005,000 |
| Pensionand Other Post Retirement Benefit Plans Current | - | - | - | $1,828,000 |
| Available For Sale Securities | - | - | - | $403,013,000 |
| Accumulated Depreciation | - | - | - | $-11,103,000 |
| Leases | - | - | - | $3,447,000 |
| Machinery Furniture Equipment | - | - | - | $1,266,000 |
| Properties | - | - | - | $0 |
Fetched: 2026-06-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $186,431,000 | $184,420,000 | $140,653,000 | $201,659,000 |
| Operating Activities | ||||
| Operating Cash Flow | $196,930,000 | $188,690,000 | $141,064,000 | $201,726,000 |
| Cash Flow From Continuing Operating Activities | $196,930,000 | $188,690,000 | $141,064,000 | $201,726,000 |
| Operating Gains Losses | $9,368,000 | - | $-77,392,000 | $-246,034,000 |
| Investing Activities | ||||
| Capital Expenditure | $-10,499,000 | $-4,270,000 | $-411,000 | $-67,000 |
| Investing Cash Flow | $40,496,000 | $-63,786,000 | $-66,761,000 | $-56,634,000 |
| Cash Flow From Continuing Investing Activities | $40,496,000 | $-63,786,000 | $-66,761,000 | $-56,634,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-4,675,000 | $-14,919,000 | $-75,805,000 | $-8,585,000 |
| Issuance Of Capital Stock | $2,553,000 | $1,466,000 | $170,000 | $370,000 |
| Financing Cash Flow | $8,551,000 | $-13,453,000 | $-171,839,000 | $-55,568,000 |
| Cash Flow From Continuing Financing Activities | $8,551,000 | $-13,453,000 | $-171,839,000 | $-55,568,000 |
| Net Other Financing Charges | $-25,000 | - | - | $-134,758,000 |
| Net Common Stock Issuance | $-2,122,000 | $-13,453,000 | $-75,635,000 | $-8,215,000 |
| Common Stock Issuance | $2,553,000 | $1,466,000 | $170,000 | $370,000 |
| Cash Dividends Paid | - | - | - | - |
| Common Stock Dividend Paid | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $0 | $0 | $-96,204,000 | $-165,131,000 |
| Interest Paid Supplemental Data | $10,353,000 | $10,359,000 | $11,381,000 | $11,736,000 |
| Income Tax Paid Supplemental Data | $19,113,000 | $11,793,000 | $0 | $53,855,000 |
| End Cash Position | $550,941,000 | $304,964,000 | $193,513,000 | $291,049,000 |
| Beginning Cash Position | $304,964,000 | $193,513,000 | $291,049,000 | $201,525,000 |
| Changes In Cash | $245,977,000 | $111,451,000 | $-97,536,000 | $89,524,000 |
| Proceeds From Stock Option Exercised | $10,698,000 | $0 | $0 | $125,000 |
| Common Stock Payments | $-4,675,000 | $-14,919,000 | $-75,805,000 | $-8,585,000 |
| Net Issuance Payments Of Debt | $0 | $0 | $-96,204,000 | $87,405,000 |
| Net Short Term Debt Issuance | $0 | $0 | $-96,204,000 | $-165,131,000 |
| Short Term Debt Payments | $0 | $0 | $-96,204,000 | $-165,131,000 |
| Net Investment Purchase And Sale | $22,819,000 | $-103,103,000 | $-107,686,000 | $-87,096,000 |
| Sale Of Investment | $101,218,000 | $0 | $0 | $0 |
| Purchase Of Investment | $-78,399,000 | $-103,103,000 | $-107,686,000 | $-87,096,000 |
| Net Business Purchase And Sale | $28,164,000 | $43,486,000 | $41,336,000 | $30,529,000 |
| Sale Of Business | $28,164,000 | $75,756,000 | $72,500,000 | $295,542,000 |
| Purchase Of Business | $0 | $-32,270,000 | $-31,164,000 | $-265,013,000 |
| Net Intangibles Purchase And Sale | $-9,368,000 | $-4,000,000 | $0 | $0 |
| Purchase Of Intangibles | $-9,368,000 | $-4,000,000 | $0 | $0 |
| Net PPE Purchase And Sale | $-1,119,000 | $-169,000 | $-411,000 | $-67,000 |
| Sale Of PPE | $12,000 | $101,000 | $0 | $0 |
| Purchase Of PPE | $-1,131,000 | $-270,000 | $-411,000 | $-67,000 |
| Change In Working Capital | $-24,162,000 | $-6,934,000 | $-24,791,000 | $6,866,000 |
| Change In Other Working Capital | $3,144,000 | $-151,000 | $-817,000 | $-755,000 |
| Change In Other Current Assets | $-1,078,000 | $-38,186,000 | $-2,965,000 | $-3,341,000 |
| Change In Payables And Accrued Expense | $-700,000 | $39,935,000 | $3,068,000 | $22,238,000 |
| Change In Accrued Expense | $-7,594,000 | $3,044,000 | $-2,435,000 | $12,120,000 |
| Change In Interest Payable | $-1,804,000 | $0 | $-937,000 | $207,000 |
| Change In Payable | $6,894,000 | $36,891,000 | $5,503,000 | $10,118,000 |
| Change In Account Payable | $2,834,000 | $-4,585,000 | $3,778,000 | $92,000 |
| Change In Tax Payable | $4,060,000 | $41,476,000 | $1,725,000 | $10,026,000 |
| Change In Income Tax Payable | $4,060,000 | $41,476,000 | $1,725,000 | $10,026,000 |
| Change In Prepaid Assets | $-5,658,000 | $567,000 | $7,929,000 | $-21,350,000 |
| Change In Inventory | $-12,919,000 | $-6,808,000 | $-12,004,000 | $280,000 |
| Change In Receivables | $-6,951,000 | $-2,291,000 | $-20,002,000 | $9,794,000 |
| Changes In Account Receivables | $-14,574,000 | $-5,938,000 | $-5,053,000 | $-3,525,000 |
| Other Non Cash Items | $22,576,000 | $29,159,000 | $42,633,000 | $29,411,000 |
| Stock Based Compensation | $9,452,000 | $6,374,000 | $5,837,000 | $7,347,000 |
| Unrealized Gain Loss On Investment Securities | $-161,593,000 | $123,414,000 | $-88,521,000 | $153,287,000 |
| Deferred Tax | $43,847,000 | $-12,617,000 | $4,400,000 | $25,006,000 |
| Deferred Income Tax | $43,847,000 | $-12,617,000 | $4,400,000 | $25,006,000 |
| Depreciation Amortization Depletion | $26,277,000 | $25,902,000 | $21,784,000 | $5,581,000 |
| Depreciation And Amortization | $26,277,000 | $25,902,000 | $21,784,000 | $5,581,000 |
| Amortization Cash Flow | $26,277,000 | $25,902,000 | $21,784,000 | $5,581,000 |
| Amortization Of Intangibles | $26,277,000 | $25,902,000 | $21,784,000 | $5,581,000 |
| Gain Loss On Sale Of PPE | $9,368,000 | $0 | $0 | - |
| Net Income From Continuing Operations | $271,165,000 | $23,392,000 | $179,722,000 | $220,262,000 |
| Issuance Of Debt | - | $0 | $0 | $252,536,000 |
| Net Long Term Debt Issuance | - | $0 | $0 | $252,536,000 |
| Long Term Debt Issuance | - | $0 | $0 | $252,536,000 |
| Gain Loss On Sale Of Business | - | $0 | $0 | $-266,696,000 |
| Earnings Losses From Equity Investments | - | - | $-77,392,000 | $161,749,000 |
| Amortization Of Securities | - | - | - | $0 |
| Depreciation | - | - | - | $892,000 |
| Long Term Debt Payments | - | - | - | - |
| Change In Other Current Liabilities | - | - | - | - |
| Asset Impairment Charge | - | - | - | - |
Fetched: 2026-06-25